Insulet Corporation (NASDAQ:PODD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Insulet Corporation (NASDAQ:PODD) have been given a consensus recommendation of “Moderate Buy” by the twenty-four ratings firms that are presently covering the firm, Marketbeat.com reports. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and twenty have given a buy rating to the company. The average twelve-month price target among brokerages that have updated their coverage on the stock in the last year is $354.2381.

PODD has been the topic of a number of research analyst reports. Stifel Nicolaus reduced their price target on Insulet from $370.00 to $350.00 and set a “buy” rating on the stock in a report on Wednesday, February 4th. The Goldman Sachs Group cut their price objective on Insulet from $363.00 to $326.00 and set a “buy” rating on the stock in a research report on Thursday, February 19th. Barclays reissued an “underweight” rating and set a $286.00 target price on shares of Insulet in a research note on Thursday, February 19th. Sanford C. Bernstein decreased their target price on Insulet from $380.00 to $330.00 and set an “outperform” rating for the company in a report on Thursday, February 19th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $380.00 price target on shares of Insulet in a research note on Wednesday, February 18th.

Insider Activity at Insulet

In related news, Director Michael R. Minogue bought 2,030 shares of the company’s stock in a transaction dated Wednesday, February 25th. The stock was purchased at an average cost of $246.23 per share, with a total value of $499,846.90. Following the transaction, the director owned 17,483 shares in the company, valued at approximately $4,304,839.09. This trade represents a 13.14% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.39% of the company’s stock.

Hedge Funds Weigh In On Insulet

A number of institutional investors have recently bought and sold shares of the stock. Rockefeller Capital Management L.P. lifted its holdings in Insulet by 488.6% in the fourth quarter. Rockefeller Capital Management L.P. now owns 3,343 shares of the medical instruments supplier’s stock worth $950,000 after buying an additional 2,775 shares during the period. Corient Private Wealth LLC grew its holdings in shares of Insulet by 35.0% during the 4th quarter. Corient Private Wealth LLC now owns 14,595 shares of the medical instruments supplier’s stock worth $4,160,000 after acquiring an additional 3,782 shares during the period. Sit Investment Associates Inc. raised its position in shares of Insulet by 13.9% in the 4th quarter. Sit Investment Associates Inc. now owns 18,634 shares of the medical instruments supplier’s stock worth $5,297,000 after acquiring an additional 2,277 shares in the last quarter. MidFirst Bank bought a new position in shares of Insulet in the 4th quarter worth approximately $394,000. Finally, Kera Capital Partners Inc. lifted its stake in shares of Insulet by 92.0% in the 4th quarter. Kera Capital Partners Inc. now owns 1,966 shares of the medical instruments supplier’s stock valued at $559,000 after purchasing an additional 942 shares during the period.

Insulet Trading Down 0.1%

Shares of PODD opened at $230.28 on Friday. The stock has a market capitalization of $16.21 billion, a P/E ratio of 65.79, a PEG ratio of 1.38 and a beta of 1.42. Insulet has a twelve month low of $216.49 and a twelve month high of $354.88. The company has a quick ratio of 2.15, a current ratio of 2.81 and a debt-to-equity ratio of 0.61. The firm has a fifty day simple moving average of $254.64 and a two-hundred day simple moving average of $294.78.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Wednesday, February 18th. The medical instruments supplier reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.07. The firm had revenue of $783.80 million for the quarter, compared to analysts’ expectations of $768.31 million. Insulet had a net margin of 9.12% and a return on equity of 24.90%. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.15 earnings per share. On average, research analysts anticipate that Insulet will post 3.92 EPS for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.